Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Johan Skog is active.

Publication


Featured researches published by Johan Skog.


Journal of Virology | 2007

Adenoviruses Use Lactoferrin as a Bridge for CAR-Independent Binding to and Infection of Epithelial Cells

Cecilia Johansson; Mari Jonsson; Marko Marttila; David Persson; Xiaolong Fan; Johan Skog; Lars Frängsmyr; Göran Wadell; Niklas Arnberg

ABSTRACT Most adenoviruses bind to the coxsackie- and adenovirus receptor (CAR). Surprisingly, CAR is not expressed apically on polarized cells and is thus not easily available to viruses. Consequently, alternative mechanisms for entry of coxsackievirus and adenovirus into cells have been suggested. We have found that tear fluid promotes adenovirus infection, and we have identified human lactoferrin (HLf) as the tear fluid component responsible for this effect. HLf alone was found to promote binding of adenovirus to epithelial cells in a dose-dependent manner and also infection of epithelial cells by adenovirus. HLf was also found to promote gene delivery from an adenovirus-based vector. The mechanism takes place at the binding stage and functions independently of CAR. Thus, we have identified a novel binding mechanism whereby adenovirus hijacks HLf, a component of the innate immune system, and uses it as a bridge for attachment to host cells.


Journal of General Virology | 2002

Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumour origin.

Johan Skog; Ya-Fang Mei; Göran Wadell

Most currently used adenovirus vectors are based upon adenovirus serotypes 2 and 5 (Ad2 and Ad5), which have limited efficiencies for gene transfer to human neural cells. Both serotypes bind to the known adenovirus receptor, CAR (coxsackievirus and adenovirus receptor), and have restricted cell tropism. The purpose of this study was to find vector candidates that are superior to Ad5 in infecting human neural tumours. Using flow cytometry, the vector candidates Ad4p, Ad11p and Ad17p were compared to the commonly used adenovirus vector Ad5v for their binding capacity to neural cell lines derived from glioblastoma, medulloblastoma and neuroblastoma cell lines. The production of viral structural proteins and the CAR-binding properties of the different serotypes were also assessed in these cells. Computer-based models of the fibre knobs of Ad4p and Ad17 were created based upon the crystallized fibre knob structure of adenoviruses and analysed for putative receptor-interacting regions that differed from the fibre knob of Ad5. The non CAR-binding vector candidate Ad11p showed clearly the best binding capacity to all of the neural cell lines, binding more than 90% of cells of all of the neural cell lines tested, in contrast to 20% or less for the commonly used vector Ad5v. Ad4p and Ad11p were also internalized and produced viral proteins more successfully than Ad5. Ad4p showed a low binding ability but a very efficient capacity for infection in cell culture. Ad17p virions neither bound or efficiently infected any of the neural cell lines studied.


Expert Review of Vaccines | 2006

Glioma-specific antigens for immune tumor therapy.

Johan Skog

This review describes glioma-specific antigens important in immunotherapy of glioma tumors. The structure and function of these antigens and recent immunotherapy data are summarized. Also, some important aspects of tumor formation are outlined. The roles of neuronal precursor cells and tumor stroma cells are discussed. The stroma cells of the tumor may be of interest as a target for tumor therapy, especially since they are less heterogeneous than the tumor cells. To date, the clinical benefit of immunotherapy has been very limited. Immunotherapy is, however, still an extremely promising approach to tumor therapy and it will most likely be implemented as a future treatment option for many types of tumors. The current shortcomings of immunotherapy will probably diminish as we start to understand and are able to modulate tumor-induced immunosuppression. There is also a need for a continued search for new tumor-specific antigens and to optimize protocols for vaccine administration.


Journal of General Virology | 2003

Comparative analysis of the genome organization of human adenovirus 11, a member of the human adenovirus species B, and the commonly used human adenovirus 5 vector, a member of species C.

Ya-Fang Mei; Johan Skog; Kristina Lindman; Göran Wadell


Molecular Therapy | 2007

Adenoviruses 16 and CV23 Efficiently Transduce Human Low-passage Brain Tumor and Cancer Stem Cells

Johan Skog; Karin Edlund; A. Tommy Bergenheim; Göran Wadell


Journal of General Virology | 2004

Efficient internalization into low-passage glioma cell lines using adenoviruses other than type 5: an approach for improvement of gene delivery to brain tumours

Johan Skog; Karin Edlund; Bengt Widegren; Leif G. Salford; Göran Wadell; Ya-Fang Mei


Archive | 2002

VIRAL VECTOR FOR GENE THERAPY

Goeran Wadell; Ya-Fang Mei; Anna Segerman; Johan Skog; Kristina Lindman


Archive | 2002

Viral vectors for gene therapy

Göran Wadell; Ya-Fang Mei; Anna Segerman; Johan Skog; Kristina Lindman


Molecular Therapy | 2006

384. Species B Adenovirus and Hematopoietic Cells Revisited

Goeran Wadell; Anna Segerman; William Burmeister; Steven Cusack; Emma K. Andersson; Karin Edlund; Praveen Papareddy; Dan J. Gustafsson; Kristina Lindman; Marko Marttila; Johan Skog; Niklas Arnberg; Ya-Fang Mei


Molecular Therapy | 2006

148. Characterisation of a Chimpanzee Adenovirus That Is Highly Infectious to Human Low-Passage Glioma Cells

Johan Skog; Emma K. Andersson; Karin Edlund; Ya-Fang Mei; Göran Wadell

Collaboration


Dive into the Johan Skog's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge